These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
213 related items for PubMed ID: 3772911
1. Arteriosclerosis risk. The roles of oral contraceptives and postmenopausal estrogens. Knopp RH. J Reprod Med; 1986 Sep; 31(9 Suppl):913-21. PubMed ID: 3772911 [Abstract] [Full Text] [Related]
2. Arteriosclerosis risk in women and the role of oral contraceptive progestins. Knopp RH. Int J Fertil; 1986 Sep; 31 SU [UPDATE]():20-30. PubMed ID: 2899556 [Abstract] [Full Text] [Related]
3. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. Wahl P, Walden C, Knopp R, Hoover J, Wallace R, Heiss G, Rifkind B. N Engl J Med; 1983 Apr 14; 308(15):862-7. PubMed ID: 6572785 [Abstract] [Full Text] [Related]
5. Oral contraceptives and the risk of cardiovascular disease. Med Lett Drugs Ther; 1983 Jul 22; 25(640):69-70. PubMed ID: 6865850 [Abstract] [Full Text] [Related]
9. Lipid and lipoprotein changes in relation to oral contraception and hormonal replacement therapy. Burkman RT. Fertil Steril; 1988 May 22; 49(5 Suppl 2):39S-50S. PubMed ID: 3282934 [Abstract] [Full Text] [Related]
10. The adverse effects of hormonal therapy. Bush TL. Cardiol Clin; 1986 Feb 22; 4(1):145-52. PubMed ID: 3518931 [Abstract] [Full Text] [Related]
11. [Cardiovascular risks of oral contraceptives: dose-response relationship]. Kelleher CC. Contracept Fertil Sex (Paris); 1991 Apr 22; 19(4):285-8. PubMed ID: 12343220 [Abstract] [Full Text] [Related]
12. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel. Teichmann A. Int J Fertil Menopausal Stud; 1995 Apr 22; 40 Suppl 2():98-104. PubMed ID: 8574257 [Abstract] [Full Text] [Related]
13. Noncontraceptive estrogen use and cardiovascular disease. Bush TL, Barrett-Connor E. Epidemiol Rev; 1985 Apr 22; 7():89-104. PubMed ID: 2996919 [Abstract] [Full Text] [Related]
14. The formulation of oral contraceptives: does the amount of estrogen make any clinical difference? Speroff L. Johns Hopkins Med J; 1982 May 22; 150(5):170-6. PubMed ID: 7043035 [Abstract] [Full Text] [Related]
15. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women. Davis SR, Goldstat R, Newman A, Berry K, Burger HG, Meredith I, Koch K. Climacteric; 2002 Dec 22; 5(4):341-50. PubMed ID: 12626213 [Abstract] [Full Text] [Related]
16. The effects of postmenopausal estrogen therapy on the incidence of arteriosclerotic vascular disease. Knopp RH. Obstet Gynecol; 1988 Nov 22; 72(5 Suppl):23S-30S. PubMed ID: 3050656 [Abstract] [Full Text] [Related]
17. [Lipids, lipoproteins, arterial accidents and oral contraceptives]. Bakir R, Hilliquin P. Contracept Fertil Sex (Paris); 1986 Jan 22; 14(1):81-7. PubMed ID: 12341243 [Abstract] [Full Text] [Related]
18. Oral contraceptives and cardiovascular risk. Taking a safe course of action. Derman RJ. Postgrad Med; 1990 Sep 15; 88(4):119-22. PubMed ID: 2204902 [Abstract] [Full Text] [Related]
19. Oral contraception: past, present, and future perspectives. Mishell DR. Int J Fertil; 1992 Sep 15; 37 Suppl 1():7-18. PubMed ID: 1347521 [Abstract] [Full Text] [Related]
20. [Hormone substitution in the menopause: effect on lipids and cardiovascular risk]. Keller U. Schweiz Rundsch Med Prax; 1991 Apr 16; 80(16):413-7. PubMed ID: 2038637 [Abstract] [Full Text] [Related] Page: [Next] [New Search]